Wave Life Sciences Files 8-K for 'Other Events' on Jan 4, 2024

TL;DR

**Wave Life Sciences filed a routine 8-K, no major news.**

AI Summary

Wave Life Sciences Ltd. filed an 8-K on January 4, 2024, under the 'Other Events' category. This filing indicates a routine disclosure of information that doesn't fall under specific enumerated items, but the company deems it important for investors. For shareholders, this filing itself doesn't reveal new material financial or operational news, but rather serves as a procedural update, signaling that the company is adhering to its reporting obligations.

Why It Matters

This filing is a standard procedural update, indicating compliance with SEC reporting requirements rather than disclosing new material information. It matters as it confirms the company's adherence to regulatory obligations.

Risk Assessment

Risk Level: low — This 8-K filing is for 'Other Events' and does not contain any specific disclosures that would indicate a change in the company's risk profile.

Analyst Insight

Investors should note this is a routine compliance filing and does not contain new material information. No immediate action is suggested based solely on this 'Other Events' 8-K.

Key Players & Entities

• Wave Life Sciences Ltd. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of earliest event reported and filing date
• 001-37627 (string) — Commission File Number for Wave Life Sciences Ltd.

FAQ

Key Financial Figures

• $0 — of each exchange on which registered $0 Par Value Ordinary Shares WVE The N
• $5.00 — nary shares at a price to the public of $5.00 per ordinary share, pursuant to a regis
• $115 m — ny received aggregate gross proceeds of $115 million, before deducting underwriting di

Filing Documents

• d681715d8k.htm (8-K) — 21KB
• 0001193125-24-002437.txt ( ) — 140KB
• wve-20240104.xsd (EX-101.SCH) — 3KB
• wve-20240104_lab.xml (EX-101.LAB) — 18KB
• wve-20240104_pre.xml (EX-101.PRE) — 11KB
• d681715d8k_htm.xml (XML) — 3KB

01

Item 8.01 Other Events. As previously disclosed, on December 7, 2023, Wave Life Sciences Ltd. (the "Company") announced the pricing of an underwritten public offering (the "Offering") of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share, pursuant to a registration statement on Form S-3 (File No. 333-263251) filed previously with the U.S. Securities and Exchange Commission, and on December 11, 2023, the Company closed the Offering. In addition, on January 4, 2024, the Company closed on the sale of an additional 3,000,000 ordinary shares after J.P. Morgan Securities LLC and Leerink Partners LLC, the representatives of the underwriters in connection with the Offering, exercised their option to purchase additional shares in the Offering in full, which increased the aggregate number of ordinary shares sold in the Offering to 23,000,000. The Company received aggregate gross proceeds of $115 million, before deducting underwriting discounts and commissions and offering expenses, in the Offering.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WAVE LIFE SCIENCES LTD. By: /s/ Paul B. Bolno, M.D. Paul B. Bolno, M.D. President and Chief Executive Officer Date: January 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR